首页> 外文期刊>American Journal of Infectious Diseases and Microbiology >Development of Sequence Based Molecular Diagnostic Test to Evaluate MDR and XDR in M. tuberculosis Patients from Western India
【24h】

Development of Sequence Based Molecular Diagnostic Test to Evaluate MDR and XDR in M. tuberculosis Patients from Western India

机译:开发基于序列的分子诊断测试以评估印度西部结核分枝杆菌患者的MDR和XDR

获取原文
       

摘要

Globally, Tuberculosis is the most distress disease which remains as a major challenge from the standpoint of diagnosis, detection of drug resistance, and treatment. The increasing knowledge in molecular biology techniques has improved our understanding of the molecular mechanisms of drug resistance for the major first and second-line anti- tubercular drugs. Thus, rapid and accurate diagnosis of Tuberculosis would improve patient care and limit its transmission. This study is aimed to identify mutations in drug resistance genes of first and second line drugs against Mycobacterium tuberculosis by using polymerase chain reaction (PCR) and DNA sequencing methods. This study involves sputum samples of 20 patients diagnosed to have pulmonary tuberculosis. The genomic DNA from clinical isolates was isolated using simple boiling method. PCR amplification and DNA sequencing were performed for katG, inhA, ndh, kasA, pncA, embB, rrs, rpsL, rpoB, gyrA, gyrB and thyA genes. Sequence analysis was done using Bioedit, a bioinformatics tool. The isolates of Mycobacterium tuberculosis from western part of India were analyzed by DNA sequencing revealed total 29 mutations in first line drugs. Out of them, 5(25%) in rpoB at codon 516 and 531, 6(30%) in katG at codon 315, 8(40%) in rpsL at codon 43 & 88, 3(15%) in embB at codon 306 and 7(35%) in pncA at codon 195.No mutations in inhA, ndh, kasA and rrs genes were observed in our study. In the second line drugs, 2(10%) at codon 90 & 100% mutations at codon 95 in gyrA gene, and no mutation in gyrB and thyA genes were observed.
机译:从诊断,耐药性检测和治疗的角度来看,结核病是全球最困扰的疾病,仍然是主要挑战。分子生物学技术知识的不断增长,使我们对主要的一线和二线抗结核药物耐药性的分子机制有了更深入的了解。因此,快速准确地诊断结核病将改善患者护理并限制其传播。本研究旨在通过聚合酶链反应(PCR)和DNA测序方法鉴定一线和二线药物对结核分枝杆菌的耐药基因中的突变。这项研究涉及20名被诊断患有肺结核的患者的痰标本。使用简单的煮沸方法从临床分离物中分离出基因组DNA。对katG,inhA,ndh,kasA,pncA,embB,rrs,rpsL,rpoB,gyrA,gyrB和thyA基因进行PCR扩增和DNA测序。使用生物信息学工具Bioedit完成了序列分析。通过DNA测序分析了印度西部结核分枝杆菌的分离株,发现一线药物中共有29个突变。其中,在516和531密码子处rpoB占5(25%),在315密码子处katG占6(30%),在43和88密码子处rpsL占8(40%),在emb密码子处占3(15%)。密码子195的pncA分别为306和7(35%)。在我们的研究中未观察到inhA,ndh,kasA和rrs基因突变。在第二线药物中,gyrA基因中第90位密码子有2(10%)和95位密码子有100%突变,而在gyrB和thyA基因中没有观察到突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号